VBI Vaccines, Inc. (VBIV) Upgraded at Zacks Investment Research
Zacks Investment Research upgraded shares of VBI Vaccines, Inc. (NASDAQ:VBIV) from a sell rating to a hold rating in a research report sent to investors on Wednesday morning.
According to Zacks, “VBI Vaccines Inc. is a biopharmaceutical company developing novel technologies to expand vaccine protection. The company’s eVLP vaccine platform allows for the design of enveloped virus-like particle vaccines which closely mimic the target virus. Its lead eVLP asset is a prophylactic cytomegalovirus vaccine. Its second platform is a thermostable technology that enables the development of vaccines and biologics. VBI Vaccines Inc., formerly known as SciVac Therapeutics, Inc., is headquartered in Cambridge, MA. “
Several other equities analysts have also recently weighed in on the stock. ValuEngine raised shares of VBI Vaccines from a sell rating to a hold rating in a research note on Wednesday, July 12th. Noble Financial reissued a buy rating on shares of VBI Vaccines in a research note on Monday, May 15th. Finally, TheStreet cut shares of VBI Vaccines from a c- rating to a d+ rating in a research note on Wednesday, May 31st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company. The company currently has a consensus rating of Hold and an average target price of $5.38.
VBI Vaccines (NASDAQ VBIV) opened at 3.42 on Wednesday. The stock has a 50 day moving average of $4.13 and a 200-day moving average of $4.57. The stock’s market cap is $137.58 million. VBI Vaccines has a 52 week low of $2.75 and a 52 week high of $6.60.
ILLEGAL ACTIVITY NOTICE: “VBI Vaccines, Inc. (VBIV) Upgraded at Zacks Investment Research” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/08/26/vbi-vaccines-inc-vbiv-upgraded-at-zacks-investment-research.html.
In other VBI Vaccines news, CEO Jeff Baxter purchased 10,000 shares of the business’s stock in a transaction on Monday, August 21st. The stock was acquired at an average price of $3.22 per share, with a total value of $32,200.00. Following the acquisition, the chief executive officer now directly owns 120,255 shares of the company’s stock, valued at approximately $387,221.10. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have acquired a total of 23,000 shares of company stock valued at $74,510 in the last ninety days. Insiders own 54.50% of the company’s stock.
A number of large investors have recently made changes to their positions in the stock. Bank of Montreal Can increased its stake in shares of VBI Vaccines by 66.5% in the first quarter. Bank of Montreal Can now owns 58,398 shares of the biopharmaceutical company’s stock valued at $321,000 after buying an additional 23,322 shares in the last quarter. EAM Investors LLC acquired a new stake in shares of VBI Vaccines during the first quarter valued at about $414,000. KCG Holdings Inc. acquired a new stake in shares of VBI Vaccines during the first quarter valued at about $512,000. Goldman Sachs Group Inc. acquired a new stake in shares of VBI Vaccines during the first quarter valued at about $383,000. Finally, Schwab Charles Investment Management Inc. acquired a new stake in shares of VBI Vaccines during the second quarter valued at about $187,000. 29.49% of the stock is owned by institutional investors and hedge funds.
About VBI Vaccines
VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for VBI Vaccines Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines Inc. and related stocks with our FREE daily email newsletter.